<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11585368
   </pmid>
   <datecreated>
    <year>
     2001
    </year>
    <month>
     10
    </month>
    <day>
     04
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2001
    </year>
    <month>
     11
    </month>
    <day>
     01
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     10
    </month>
    <day>
     24
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1530-891X
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       7
      </volume>
      <issue>
       5
      </issue>
      <pubdate>
       <medlinedate>
        2001 Sep-Oct
       </medlinedate>
      </pubdate>
     </journalissue>
     <title>
      Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
     </title>
     <isoabbreviation>
      Endocr Pract
     </isoabbreviation>
    </journal>
    <articletitle>
     Autoantibodies to IA-2 and GAD65 in patients with type 2 diabetes mellitus of varied duration: prevalence and correlation with clinical features.
    </articletitle>
    <pagination>
     <medlinepgn>
      339-45
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine the prevalence of autoantibodies to IA-2 (IA-2Ab) and glutamic acid decarboxylase (GADAb) in type 2 diabetes, their relationship to disease duration, and their importance in management decisions.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      We undertook a study of 101 patients with type 2 diabetes (defined as nonketotic hyperglycemia at diagnosis) of varied duration (median, 4 years). Results were compared with those from 36 patients with type 1 diabetes also of varied duration (median, 2 years). IA-2Ab and GADAb were measured by radioligand-binding assays with use of in vitro-synthesized, 35S-labeled antigens.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Of the 101 patients with type 2 diabetes, 20 (20%) were positive for GADAb; only 4 of these 20 were positive for IA-2Ab. In comparison, 75% of patients with type 1 diabetes were positive for GADAb, IA-2Ab, or both (P&lt;0.0001). The coincidence of IA-2Ab positivity in GADAb-positive patients with type 2 diabetes was significantly lower than in patients with type 1 diabetes (20% versus 73%, respectively; P = 0.002). All four IA-2Ab- and GADAb-positive patients with type 2 diabetes required insulin and were younger than those positive for GADAb alone (P = 0.018). GADAb positivity in patients with type 2 diabetes was highly associated with insulin requirement (P = 0.004), with an odds ratio of 5.8 in predicting insulin dependence. Among patients with type 2 diabetes receiving insulin therapy, disease duration was significantly shorter (P = 0.025) and body mass index was significantly lower (P&lt;0.001) in GADAb-positive versus GADAb-negative patients. In contrast to type 1 diabetes, in which GADAb values were negatively correlated with disease duration (r = -0.34; P = 0.044), no significant correlation with disease duration was observed in type 2 diabetes (r = -0.166; P = 0.48).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Irrespective of duration of disease, measurement of IA-2Ab and GADAb can help to identify those patients with type 2 diabetes most likely to require insulin therapy.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Clinical Pathology, L30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Grasso
      </lastname>
      <forename>
       Y Z
      </forename>
      <initials>
       YZ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Reddy
      </lastname>
      <forename>
       S K
      </forename>
      <initials>
       SK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Rosenfeld
      </lastname>
      <forename>
       C R
      </forename>
      <initials>
       CR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hussein
      </lastname>
      <forename>
       W I
      </forename>
      <initials>
       WI
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hoogwerf
      </lastname>
      <forename>
       B J
      </forename>
      <initials>
       BJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Faiman
      </lastname>
      <forename>
       C
      </forename>
      <initials>
       C
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Gupta
      </lastname>
      <forename>
       M K
      </forename>
      <initials>
       MK
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Endocr Pract
    </medlineta>
    <nlmuniqueid>
     9607439
    </nlmuniqueid>
    <issnlinking>
     1530-891X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Autoantibodies
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      ICA512 autoantibody
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Isoenzymes
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      EC 4.1.1.15
     </registrynumber>
     <nameofsubstance>
      Glutamate Decarboxylase
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      EC 4.1.1.15
     </registrynumber>
     <nameofsubstance>
      glutamate decarboxylase 2
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Endocr Pract. 2001 Sep-Oct;7(5):407-8
     </refsource>
     <pmid version="1">
      11585380
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Autoantibodies
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetes Mellitus, Type 1
     </descriptorname>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetes Mellitus, Type 2
     </descriptorname>
     <qualifiername majortopicyn="Y">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Glutamate Decarboxylase
     </descriptorname>
     <qualifiername majortopicyn="Y">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Isoenzymes
     </descriptorname>
     <qualifiername majortopicyn="Y">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2001
     </year>
     <month>
      10
     </month>
     <day>
      5
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2001
     </year>
     <month>
      11
     </month>
     <day>
      3
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2001
     </year>
     <month>
      10
     </month>
     <day>
      5
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11585368
    </articleid>
    <articleid idtype="pii">
     EP0106.OR
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

